NSE · CAPLIPOINT
Caplin Point Laboratories Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹203 Cr with net profit ₹120 Cr — a 59.32% net margin, versus 27.85% the period before.
Shareholding
As of 2026-06-30
- Promoter70.57%
- Public21.18%
- FII5.75%
- DII2.49%
94,385 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.92× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #5 of 50 by market cap · medians across 43 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,83,052 Cr | 82.04 | 21.82 | 25.49% | 13.95% |
| Gland Pharma Limited | ₹46,642 Cr | 40.71 | 4.51 | 9.92% | 16.78% |
| Ajanta Pharma Limited | ₹43,847 Cr | 38.64 | 9.66 | 23.33% | 19.65% |
| Rubicon Research Limited | ₹29,245 Cr | 101.48 | 22.65 | 19.14% | 14.89% |
| Caplin Point Laboratories Ltd.(this company) | ₹19,634 Cr | 29.51 | 5.83 | 17.88% | 29.09% |
| Shilpa Medicare Ltd. | ₹18,151 Cr | 63.83 | 7 | 9.39% | 17.67% |
| Eris Lifesciences Limited | ₹18,060 Cr | 27.49 | 4.64 | 15.87% | 20.04% |
| Marksans Pharma Limited | ₹14,340 Cr | 27.76 | 4.74 | 13.82% | 16.29% |
| Bliss GVS Pharma Ltd. | ₹7,236 Cr | 52.55 | 6.06 | 10.82% | 13.55% |
| Senores Pharmaceuticals Limited | ₹6,341 Cr | 50.18 | 6.76 | 12.36% | 18.59% |
AI analysis
AI-generated · google/gemini-2.5-flashCaplin Point Laboratories Ltd. has a market capitalization of Rs 20137 Cr. The company reported revenue of Rs 2033.9 Cr, with revenue growth of 14.4%. Profit margin stands at 29.32%. The company's EPS is Rs 84.36, and it has a PE ratio of 118.37. Return on equity (ROE) is 17.88%, and return on capital employed (ROCE) is 22.2984%.
Positives
- +Revenue growth was 14.4%.
- +Profit margin is 29.32%.
- +Debt-to-equity ratio is 0, indicating no debt.
- +Promoter holding is high at 70.5712%.
- +No promoter shares are pledged.
Negatives
- −The PE ratio is high at 118.37.
- −Quarterly EPS data for all periods since June 2025 is not disclosed.
Financial Performance
Caplin Point Laboratories Ltd. achieved a revenue of Rs 2033.9 Cr, demonstrating a revenue growth of 14.4%. The annual net profit for March 2025 was Rs 536.31 Cr, with an EPS of Rs 70.25. Quarterly performance shows a net profit of Rs 170.11 Cr on a revenue of Rs 600.16 Cr for the quarter ending March 2026.
Profitability & Returns
The company maintains a profit margin of 29.32%. Its return on equity (ROE) is 17.88%, and return on capital employed (ROCE) is 22.2984%. The earnings per share (EPS) is Rs 84.36, with a PE ratio of 118.37. The company's dividend yield is 15%.
Balance Sheet
Caplin Point Laboratories Ltd. has reported a book value of Rs 471.83. The debt-to-equity ratio is 0, indicating no debt. No details regarding pledges are available.
Ownership & Pledges
As of March 31, 2026, promoter holding stands at 70.5712%. Institutional holding, comprising DII and FII, is 8.2892%. Public shareholding is 21.1396%. There are no promoter shares pledged.
Data as of — price: 2026-09-17 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Caplin Point Laboratories Ltd.share price & fundamentals